Muscle Invasive Bladder Cancer Clinical Trials

86 clinical trials for Muscle Invasive Bladder Cancer across international registries, including 21 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder — RECRUITING · PHASE2
• A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer — RECRUITING
• Diagnostic Accuracy of 18F-FDG PET/CT in Muscle-invasive Bladder Cancer — RECRUITING
• EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC — RECRUITING · PHASE2
• Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging — RECRUITING
• mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer — RECRUITING · NA
• Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence — RECRUITING · PHASE2
• Sample Collection for Ongoing Research and Product Evaluation Study — RECRUITING
• Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm — RECRUITING · NA
• Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC — RECRUITING · PHASE2
• Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations — RECRUITING · PHASE2
• Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy — RECRUITING · NA
• Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy — RECRUITING · NA
• Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer — RECRUITING · PHASE3
• Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer — RECRUITING · PHASE1
• AN OPEN-LABEL, SINGLE-ARM, GLOBAL STUDY OF PERIOPERATIVE DURVALUMAB WITH CISPLATIN-BASED NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER (NIAGARA-2) — RECRUITING · PHASE3
• Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics — RECRUITING
• A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PERIOPERATIVE ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB (MK-3475) VERSUS NEOADJUVANT GEMCITABINE AND CISPLATIN IN CISPLATIN-ELIGIBLE PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER (KEYNOTE-B15 /EV-304) — RECRUITING · PHASE3
• A PHASE 3 RANDOMIZED STUDY OF CYSTECTOMY PLUS PERIOPERATIVE PEMBROLIZUMAB VERSUS CYSTECTOMY ALONE IN CISPLATIN-INELIGIBLE PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER (KEYNOTE-905) — RECRUITING · PHASE3
• A RANDOMIZED PHASE II TRIAL ASSESSING TRIMODALITY THERAPY WITH OR WITHOUT ADJUVANT DURVALUMAB TO TREAT PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER — RECRUITING · PHASE2
• Rad-IO — OTHER · PHASE3
• An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209). — NOT_YET_RECRUITING · PHASE2
• Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer — NOT_YET_RECRUITING · PHASE2
• RESTORE-BLADDER (REgistry on STrategies for Organ pREservation in Muscle-invasive BLADDER Cancer) — NOT_YET_RECRUITING
• ACTIVE SURVEILLANCE VERSUS DEFINITIVE LOCAL THERAPY FOR PATIENTS SHOWING CLINICAL COMPLETE RESPONSE FOLLOWING NEOADJUVANT THERAPY FOR MUSCLE-INVASIVE BLADDER CANCER — NOT_YET_RECRUITING
• A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY — NOT_YET_RECRUITING · PHASE3
• Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC — ACTIVE_NOT_RECRUITING · PHASE3
• A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303) — TERMINATED · PHASE3
• A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304) — TERMINATED · PHASE3
• A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monotherapy and erdafitinib (ERDA) and cetrelimab (CET) combination as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations (SOGUG-NEOWIN) — TERMINATED · PHASE2
• Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma — NOT_YET_RECRUITING · PHASE2
• Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin — ACTIVE_NOT_RECRUITING · PHASE3
• Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer — NOT_YET_RECRUITING · PHASE2
• Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Muscle Invasive Bladder Cancer — COMPLETED
• A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Tumor Budding and T1 Substaging in Urothelial Bladder Cancer — NOT_YET_RECRUITING
• SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan, and bladder-saving approach, for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy — TERMINATED · PHASE2
• EFFICACY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER — TERMINATED · PHASE2
• A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy — ACTIVE_NOT_RECRUITING · PHASE3
• Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC — NOT_YET_RECRUITING · PHASE2
• Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy — NOT_YET_RECRUITING
• Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer — NOT_YET_RECRUITING · NA
• An open label, single-arm, phase 2 study of neoadjuvant sacituzumab govitecan, before radical cystectomy, for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy — OTHER · PHASE2
• Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• NRG-GU015: THE PHASE III ADAPTIVE RADIATION AND CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER TRIAL (ARCHER) — NOT_YET_RECRUITING · PHASE3
• Avelumab and Radiation in Muscle-Invasive Bladder Cancer — TERMINATED · PHASE2
• Bladder Preservation with Sacituzumab Govitecan + Zimberelimab for MuscleInvasive Bladder cancer in cisplatin-unfit and unwilling for cystectomy patients: phase II trial (preSAVE trial) — NOT_YET_RECRUITING · PHASE2
• Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment — NOT_YET_RECRUITING · PHASE2
• Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer — COMPLETED

Refine this search